Difluoromethylornithine

Phase 2Small molecule

CCancer Prevention Pharmaceuticals, Inc.

Difluoromethylornithine is one of 134 small molecule programs targeting Skin Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

133

Competitors

Pipeline

Status by Indication[3][1]

Indication

Skin CancerActive, not recruiting

NeuroblastomaActive, not recruiting

Type 1 DiabetesActive, not recruiting

MedulloblastomaActive, not recruiting

Skin CancerPhase 2

Active, not recruiting

NeuroblastomaPhase 2

Active, not recruiting

Type 1 DiabetesPhase 1

Active, not recruiting

MedulloblastomaPhase 2

Active, not recruiting

Competition

Competitive Landscape

384 competitors in Type 1 Diabetes

#DrugCompanyPhaseTrials

Difluoromethylornithine

CCancer Prevention Pharmaceuticals, Inc.

Phase 2

1 2

Symlin

AstraZeneca

Preclinical

3 3

Glargine

Eli Lilly

Preclinical

4 4

Cytoxan

BBaxter Healthcare Corporation

Preclinical

1 5

Feraheme

AAzurity Pharmaceuticals

Preclinical

1 6

Foradil

Viatris

Preclinical

1 7

Pitocin

RRetrophin

Preclinical

1 8

SGLT2 Inhibitor

Eli Lilly

Preclinical

1 9

Teplizumab

Sanofi

Preclinical

8 10

Mesenchymal Stem Cells

JJiangsu Topcel-KH Pharmaceutical Co., Ltd.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2029

Phase 2Recruiting

Medulloblastoma

NCT04696029

Q1 2033

Phase 2Recruiting

Neuroblastoma

NCT02679144

Clinical

Trials by Indication[1]

Medulloblastoma1 trial

DFMO as Maintenance Therapy for Molecular High/Very High Risk and Relapsed Medulloblastoma

Recruiting·GGiselle Sholler·Phase 2·NCT04696029·118 enrolled

Skin Cancer1 trial

Difluoromethylornithine (DFMO) Chemoprevention of Skin Cancer in Organ Transplant Recipients

Completed·UUniversity of Wisconsin, Madison·Phase 2·NCT00204789·52 enrolled

Type 1 Diabetes1 trial

DFMO in Children With Type 1 Diabetes

Completed·IIndiana University·Phase 1·NCT02384889·41 enrolled

NSCLC1 trial

Targeting ODC as an Immunotherapeutic Target in STK11 (LKB1) Pathway-Deficient NSCLC (DFMO)

Suspended·HH. Lee Moffitt Cancer Center and Research Institute·Phase 1/2·NCT06219174·45 enrolled

Biomarker1 trial

Urinary Biomarker Study With Sulindac and Difluoromethylornithine

Withdrawn·CCancer Prevention Pharmaceuticals, Inc.·Phase 2·NCT01636128

1 more indication

Neuroblastoma1 trial

Neuroblastoma Maintenance Therapy Trial

Recruiting·GGiselle Sholler·Phase 2·NCT02679144·441 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for Difluoromethylornithine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Difluoromethylornithine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Difluoromethylornithine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Cancer Prevention Pharmaceuticals, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: CCancer Prevention Pharmaceuticals, Inc.

Difluoromethylornithine

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2029

Q1 2033

Trials by Indication[1]

Medulloblastoma1 trial

Skin Cancer1 trial

Type 1 Diabetes1 trial

NSCLC1 trial

Biomarker1 trial

Neuroblastoma1 trial

References

Drug Info

Quick Facts

Related News